Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, President Trump picked a new U.S. Food and Drug Administration (FDA) commissioner, a study found that cervical cancer screening is lacking in a key cohort, and more.
A British study found that a self-administered home Pap smear test is feasible to screen for cervical cancer rather than in-office visits, according to a study presented at the National Cancer Research Institute 2019 Cancer Conference.
Although half of cervical cancers are diagnosed in women older than 49 years, preventive screening measures are lacking in women aged 45 and 65 years, according to a study published in Preventive Medicine.
The American College of Physicians has published its recommendations for the testing of colorectal cancer among average-risk adults.
President Donald Trump nominated Stephen Hahn, MD, to serve as the next FDA commissioner. Here are a few facts about Dr. Hahn.
Some skin cancers may begin growing in the hair follicles, according to the findings of a new study published in Nature Communications.
In case you missed it, more hem/onc headlines are featured below:
- FDA Approves Another Biosimilar for Febrile Neutropenia
- Gilteritinib Significantly Improves Survival for FLT3-Mutated Acute Myeloid Leukemia
- Patients Not Being Made Aware of Costs of Cancer Genomic Tests
- Why Do Diabetic Men Have a Lower Prostate Cancer Risk?
- Does Chemo Induce Cancer Recurrence in ALL Survivors?